Mark E. Bunnage

5.3k citations

51 papers · 2.9k indexed · 1 hit paper · h-index 30

Impact in

Organic Chemistry top 1%
- Synthetic Organic Chemistry Methods
- Asymmetric Synthesis and Catalysis
Hematology top 5%
- Multiple Myeloma Research and Treatments

Papers in ⓘ

Organic Chemistry 29
- Synthetic Organic Chemistry Methods 13
- Asymmetric Synthesis and Catalysis 8
- Oxidative Organic Chemistry Reactions 6
- Carbohydrate Chemistry and Synthesis 5
Pharmaceutical Science 3

Co-authors: Lyn H. Jones (4 shared papers)Stephen G. Davies (11 shared papers)Christopher J. Goodwin (7 shared papers)Eugene L. Piatnitski Chekler (1 shared paper)K. C. Nicolaou (9 shared papers)Kazunori Koide (6 shared papers)P. Filippakopoulos (3 shared papers)Martin Philpott (3 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (8 papers)Chemistry - A European Journal (6 papers)Organic & Biomolecular Chemistry (4 papers)Journal of Medicinal Chemistry (4 papers)Nature Chemical Biology (3 papers)
Partner nations: United Kingdom United States Switzerland

In The Last Decade

Mark E. Bunnage

50 papers receiving 2.8k citations

Hit Papers

align trajectories log scale

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants 2023 · 98 citations

Peers

Countries citing papers authored by Mark E. Bunnage

Since Specialization

Citations

This map shows the geographic impact of Mark E. Bunnage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Bunnage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Bunnage more than expected).

Fields of papers citing papers by Mark E. Bunnage

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Bunnage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Bunnage. The network helps show where Mark E. Bunnage may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark E. Bunnage, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark E. Bunnage Line = papers co-authored together Mark E. Bunnage links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Target validation using chemical probes Nature Chemical Biology ·Mark E. Bunnage, Eugene L. Piatnitski Chekler, Lyn H. Jones	2013	289
2	Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains Journal of the American Chemical Society ·Duncan A. Hay, Oleg Fedorov, Sarah Martin, Dean C. Singleton, C. Tallant, Christopher Wells, S. Picaud, Martin Philpott, Octovia Monteiro, Catherine Rogers, Stuart J. Conway, Timothy P. C. Rooney, Anthony Tumber, Clarence Yapp, P. Filippakopoulos, Mark E. Bunnage, Susanne Müller, Stefan Knapp, Christopher J. Schofield, Paul E. Brennan	2014	208
3	PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains Cancer Research ·S. Picaud, David Da Costa, Angeliki Thanasopoulou, P. Filippakopoulos, Paul V. Fish, Martin Philpott, O. Fedorov, Paul E. Brennan, Mark E. Bunnage, Dafydd R. Owen, James E. Bradner, Philippe Tanière, Brendan O’Sullivan, Susanne Müller, Juerg Schwaller, Tatjana Stanković, Stefan Knapp	2013	193
4	Getting pharmaceutical R&D back on target Nature Chemical Biology ·Mark E. Bunnage	2011	191
5	Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit Journal of Medicinal Chemistry ·Paul V. Fish, P. Filippakopoulos, Gerwyn Bish, Paul E. Brennan, Mark E. Bunnage, Andrew S. Cook, Oleg Federov, Brian S. Gerstenberger, Hannah M. Jones, Stefan Knapp, Brian D. Marsden, Karl Nocka, Dafydd R. Owen, Martin Philpott, S. Picaud, Michael J. Primiano, Michael J. Ralph, Nunzio Sciammetta, John D. Trzupek	2012	151
6	Fluorine in Drug Design: A Case Study with Fluoroanisoles ChemMedChem ·Xing Li, David C. Blakemore, Arjun Narayanan, Ray Unwalla, Frank Lovering, R. Aldrin Denny, Huanyu Zhou, Mark E. Bunnage	2015	122
7	Applications of chemogenomic library screening in drug discovery Nature Reviews Drug Discovery ·Lyn H. Jones, Mark E. Bunnage	2017	119
8	Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants New England Journal of Medicine ·Ogo Egbuna, Brandon Zimmerman, George Manos, A H Fortier, Madalina Chirieac, Leslie A. Dakin, David J. Friedman, Kate Bramham, Kirk N. Campbell, Bertrand Knebelmann, Laura Barisoni, Ronald J. Falk, Debbie S. Gipson, Michael S. Lipkowitz, Akinlolu Ojo, Mark E. Bunnage, Martin R. Pollak, David Altshuler, Glenn M. Chertow Hit paper breakdown →	2023	98
9	Total Synthesis of Balanol Journal of the American Chemical Society ·K. C. Nicolaou, Mark E. Bunnage, Kazunori Koide	1994	93
10	Crystal Structure of the Potent Natural Product Inhibitor Balanol in Complex with the Catalytic Subunit of cAMP-Dependent Protein Kinase Biochemistry ·Narendra Narayana, Thomas C. Diller, Kazunori Koide, Mark E. Bunnage, K. C. Nicolaou, Laurence L. Brunton, Nguyen‐Huu Xuong, Lynn F. Ten Eyck, Susan S. Taylor	1999	79
11	Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease Journal of Medicinal Chemistry ·David S. Millan, Mark E. Bunnage, Jane L. Burrows, Kenneth J. Butcher, Peter G. Dodd, Timothy J. Evans, David Fairman, Samantha Jane Hughes, Iain Kilty, Arnaud Lemaitre, Russell A. Lewthwaite, Axel Mahnke, John P. Mathias, James Philip, R T Smith, Mark H. Stefaniak, Michael Yeadon, Christopher Phillips	2011	76
12	Know your target, know your molecule Nature Chemical Biology ·Mark E. Bunnage, A. Gilbert, Lyn H. Jones, Erik C. Hett	2015	72
13	Total Synthesis of Brevetoxin A: Part 1: First Generation Strategy and Construction of BCD Ring System Chemistry - A European Journal ·K. C. Nicolaou, Mark E. Bunnage, Daniel McGarry, Shuhao Shi, Patricia K. Somers, Paul A. W. Wallace, Xin‐Jie Chu, Konstantinos A. Agrios, Janet L. Gunzner, Zhen Yang	1999	69
14	Inhalation by Design: Novel Ultra-Long-Acting β₂-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup Journal of Medicinal Chemistry ·Paul A. Glossop, Charlotte A. L. Lane, David Price, Mark E. Bunnage, Russell A. Lewthwaite, Kim James, Alan D. Brown, Michael Yeadon, Christelle Perros-Huguet, Michael A. Trevethick, Nicholas Clarke, Robert O. Webster, Rhys M. Jones, Jane L. Burrows, N. Feeder, Stefan C. Taylor, Fiona Spence	2010	65
15	Asymmetric synthesis of β-amino-α-hydroxy acids via diastereoselective hydroxylation of homochiral β-amino enolates Journal of the Chemical Society Perkin Transactions 1 ·Mark E. Bunnage, Alexander N. Chernega, Stephen G. Davies, Christopher J. Goodwin	1994	61
16	Asymmetric synthesis of the taxol and taxotère C-13 side chains Journal of the Chemical Society Perkin Transactions 1 ·Mark E. Bunnage, Stephen G. Davies, Christopher J. Goodwin	1994	59
17	Total Synthesis of Balanol and Designed Analogues Chemistry - A European Journal ·K. C. Nicolaou, Kazunori Koide, Mark E. Bunnage	1995	58
18	Asymmetric Synthesis of the Putative Structure of (−)-Oryzoxymycin Organic Letters ·Mark E. Bunnage, Thota Ganesh, Ishmael B. Masesane, Darren Orton, Patrick G. Steel	2003	57
19	An expeditious asymmetric synthesis of allophenylnorstatine Tetrahedron ·Mark E. Bunnage, Stephen G. Davies, Christopher J. Goodwin, Osamu Ichihara	1994	53
20	Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol Chemistry & Biology ·Kazunori Koide, Mark E. Bunnage, Luigi Gomez Paloma, Joan R. Kanter, Susan S. Taylor, Laurence L. Brunton, K. C. Nicolaou	1995	52

About Mark E. Bunnage

Mark E. Bunnage is a scholar working on Organic Chemistry, Pharmaceutical Science, Pharmacology, Environmental Chemistry and Molecular Biology, having authored 51 papers that have together received 2.9k indexed citations. Recurring topics across this work include Synthetic Organic Chemistry Methods (13 papers), Asymmetric Synthesis and Catalysis (8 papers), Protein Degradation and Inhibitors (7 papers), Microbial Natural Products and Biosynthesis (6 papers), Oxidative Organic Chemistry Reactions (6 papers), Chemical Synthesis and Analysis (5 papers), Carbohydrate Chemistry and Synthesis (5 papers) and Cancer Treatment and Pharmacology (4 papers). The work is most often cited by research in Organic Chemistry (1.3k citations), Hematology (309 citations), Molecular Biology (1.7k citations), Pharmaceutical Science (134 citations) and Computational Theory and Mathematics (300 citations). Mark E. Bunnage has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Lyn H. Jones, Stephen G. Davies, Christopher J. Goodwin, Eugene L. Piatnitski Chekler, K. C. Nicolaou, Kazunori Koide, P. Filippakopoulos, Martin Philpott, S. Picaud and Stefan Knapp. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Chemistry - A European Journal, Organic & Biomolecular Chemistry, Journal of Medicinal Chemistry and Nature Chemical Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact